Mycobacterium specific ATP synthase inhibitors as Anti-tubercular drug - Pawar, Rajesh
23,99 €
inkl. MwSt.

Versandfertig in 6-10 Tagen
  • Broschiertes Buch

Mycobacterium tuberculosis is a causative agent of tuberculosis. More than one third of the world population are infected with TB bacilli. After AIDS, tuberculosis is the leading cause of death among infectious diseases in the world. Bedaquiline, the lead compound of the DARQ series,. It also shows a selectivity of 20,000:1 towards mycobacterial ATP synthase as compared to human mitochondrial ATP synthase. Bedaquiline was recently approved for use by the U.S. Food and Drug Administration (FDA) against Multi-drug resistant TB (MDR-TB). Some new pharmacophores have been reported that are showing…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Mycobacterium tuberculosis is a causative agent of tuberculosis. More than one third of the world population are infected with TB bacilli. After AIDS, tuberculosis is the leading cause of death among infectious diseases in the world. Bedaquiline, the lead compound of the DARQ series,. It also shows a selectivity of 20,000:1 towards mycobacterial ATP synthase as compared to human mitochondrial ATP synthase. Bedaquiline was recently approved for use by the U.S. Food and Drug Administration (FDA) against Multi-drug resistant TB (MDR-TB). Some new pharmacophores have been reported that are showing Anti-TB activity. For example quinoline based compounds containing aryl allyl ether were reported to have promising activity. Quinoline are well-known pharmacophore in medicinal chemistry showing promising activity against various diseases such as antimalaria, antimicrobial and antituberculosis activity.
Autorenporträt
Rajesh Pawar is currently working as Senior Research Associate in Pharmaceutical organization. He has completed M.S.Pharm in Medicinal Chemistry from NIPER Raebareli in 2015 and his B.Pharm from RGTU Bhopal in 2013.